Continuous glucose monitoring (CGM) has revolutionized diabetes management by enabling real-time glucose tracking, improving glycemic control, and reducing the risk of complications. However, the potential of CGM systems extends beyond their current applications, and the integration of advanced technologies and analytical methods opens new opportunities to further enhance patient care. This symposium will explore the latest research and practical applications of CGM, addressing topics that play a critical role in the future of diabetes management. This symposium will provide a platform to explore how CGM technology, combined with innovative approaches, is transforming the future of diabetes care and improving patient outcomes across diverse settings.

Metabolic diseases, including obesity, diabetes, and related complications, are influenced by the complex interplay of biological pathways. Recent studies have highlighted novel molecular and cellular therapeutic targets that could lead to innovative treatment strategies. This symposium will explore groundbreaking research on the roles of inflammation, autophagy, and mitochondria-derived peptides in metabolic and aging-related diseases, focusing on potential therapeutic approaches based on these findings. Expert speakers will deliver in-depth lectures on key topics, including the role of inflammation in Metabolic dysfunction-associated fatty liver disease (MAFLD), the interplay between autophagy and inflammation in the aging process, and the novel axis of MOTS-c in aging-related muscle dysfunction. This symposium will provide a comprehensive understanding of new therapeutic targets for metabolic diseases and aging, presenting cutting-edge research that bridges basic science and clinical applications to improve health outcomes.

Cardiovascular disease (CVD) is one of the leading causes of death worldwide, highlighting the urgent need for innovative approaches to enable early detection, risk stratification, and enhanced prevention strategies. This symposium will explore cutting-edge research leveraging artificial intelligence, biomarkers, and interorgan networks for the prediction of atherosclerosis and CVD risk. In the first presentation, Professor Tyler Hyung-Tak Rim will introduce an innovative approach utilizing artificial intelligence and funduscopic vascular imaging to assess systemic health, presenting new possibilities for integrating ophthalmology and cardiology in early risk assessment. Following this, Professor Da Young Lee will discuss the latest findings on the identification and validation of novel circulating biomarkers, emphasizing their potential to establish personalized preventive strategies for patients. Finally, Professor Seung-Hwan Lee will delve into the mechanisms by which extracellular vesicles mediate interorgan signaling, providing new perspectives on the interplay between systemic health and cardiovascular disease. This symposium aims to foster collaboration and innovation in cardiovascular research, paving the way for next-generation predictive tools and therapeutic strategies.

Dyslipidemia is a major risk factor for cardiovascular disease and a key target in managing metabolic disorders. While statins and other established therapies have proven effective, new approaches are required to reduce residual cardiovascular risks and provide personalized care. This session will explore both current and future strategies in dyslipidemia management. Professor Eun-Jung Lee will introduce RNA-based therapies, including siRNA and ASOs. Professor Sung Hee Choi will present small-molecule targeted drugs that selectively regulate lipid metabolism. Lastly, Professor Youngwoo Jang will review recent advancements in biologic therapies, such as monoclonal antibodies and protein-based treatments.